These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 32172521)

  • 1. Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38%: A Review in Post-Operative Inflammation and Pain Following Ocular Surgery.
    Kang C; Keam SJ; Shirley M; Syed YY
    Clin Drug Investig; 2020 Apr; 40(4):387-394. PubMed ID: 32172521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loteprednol etabonate ophthalmic gel 0.5%: a review of its use in post-operative inflammation and pain following ocular surgery.
    Lyseng-Williamson KA
    Drugs; 2013 Jun; 73(9):949-58. PubMed ID: 23740411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of loteprednol etabonate 0.5% gel in the treatment of ocular inflammation and pain after cataract surgery.
    Rajpal RK; Roel L; Siou-Mermet R; Erb T
    J Cataract Refract Surg; 2013 Feb; 39(2):158-67. PubMed ID: 23218817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Submicron loteprednol etabonate ophthalmic gel 0.38% for the treatment of inflammation and pain after cataract surgery.
    Fong R; Silverstein BE; Peace JH; Williams JI; Vittitow JL
    J Cataract Refract Surg; 2018 Oct; 44(10):1220-1229. PubMed ID: 30193927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loteprednol etabonate ophthalmic gel 0.5% following cataract surgery: integrated analysis of two clinical studies.
    Rajpal RK; Fong R; Comstock TL
    Adv Ther; 2013 Oct; 30(10):907-23. PubMed ID: 24136301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Efficacy of Difluprednate 0.05% and Loteprednol Gel 0.5% After Cataract Surgery.
    Abessi B; Brooksby L; Schultze RL
    Eye Contact Lens; 2018 Nov; 44 Suppl 2():S37-S42. PubMed ID: 28628490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and tolerability of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension in pediatric subjects.
    Comstock TL; Paterno MR; Bateman KM; Decory HH; Gearinger M
    Paediatr Drugs; 2012 Apr; 14(2):119-30. PubMed ID: 22292487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double-masked, placebo-controlled evaluation of loteprednol etabonate 0.5% for postoperative inflammation. Loteprednol Etabonate Post-operative Inflammation Study Group 1.
    Stewart R; Horwitz B; Howes J; Novack GD; Hart K
    J Cataract Refract Surg; 1998 Nov; 24(11):1480-9. PubMed ID: 9818338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loteprednol etabonate ophthalmic suspension 0.5 %: efficacy and safety for postoperative anti-inflammatory use.
    Amon M; Busin M
    Int Ophthalmol; 2012 Oct; 32(5):507-17. PubMed ID: 22707339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Innovations in topical ocular corticosteroid therapy for the management of postoperative ocular inflammation and pain.
    Salinger CL; Gaynes BI; Rajpal RK
    Am J Manag Care; 2019 Jul; 25(12 Suppl):S215-S226. PubMed ID: 31419092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loteprednol etabonate 0.5% versus prednisolone acetate 1.0% for the treatment of inflammation after cataract surgery.
    Lane SS; Holland EJ
    J Cataract Refract Surg; 2013 Feb; 39(2):168-73. PubMed ID: 23232255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rheological Properties, Dissolution Kinetics, and Ocular Pharmacokinetics of Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38.
    Cavet ME; Glogowski S; Lowe ER; Phillips E
    J Ocul Pharmacol Ther; 2019 Jun; 35(5):291-300. PubMed ID: 30907685
    [No Abstract]   [Full Text] [Related]  

  • 13. Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on Intraocular Pressure.
    Sheppard JD; Comstock TL; Cavet ME
    Adv Ther; 2016 Apr; 33(4):532-52. PubMed ID: 26984315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loteprednol etabonate (submicron) ophthalmic gel 0.38% dosed three times daily following cataract surgery: integrated analysis of two Phase III clinical studies.
    Fong R; Cavet ME; DeCory HH; Vittitow JL
    Clin Ophthalmol; 2019; 13():1427-1438. PubMed ID: 31447544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of 2 regimens of loteprednol etabonate and bromfenac for cataract surgery.
    Al-Awadi A; Tokko HA; Chan CC; Somani S
    Can J Ophthalmol; 2019 Jun; 54(3):388-394. PubMed ID: 31109481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The conjunctival provocation test model of ocular allergy: utility for assessment of an ocular corticosteroid, loteprednol etabonate.
    Abelson M; Howes J; George M
    J Ocul Pharmacol Ther; 1998 Dec; 14(6):533-42. PubMed ID: 9867336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraocular pressure elevations with loteprednol etabonate: a retrospective chart review.
    Rajpal RK; Digby D; D'Aversa G; Mah F; Hollander DA; Conway T
    J Ocul Pharmacol Ther; 2011 Jun; 27(3):305-8. PubMed ID: 21574815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolonged exposure to loteprednol etabonate in human tear fluid and rabbit ocular tissues following topical ocular administration of Lotemax gel, 0.5%.
    Glogowski S; Lowe E; Siou-Mermet R; Ong T; Richardson M
    J Ocul Pharmacol Ther; 2014 Feb; 30(1):66-73. PubMed ID: 24325539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of postoperative inflammation. The Loteprednol Etabonate Postoperative Inflammation Study Group 2.
    Ophthalmology; 1998 Sep; 105(9):1780-6. PubMed ID: 9754192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loteprednol Etabonate for the Treatment of Dry Eye Disease.
    Beckman K; Katz J; Majmudar P; Rostov A
    J Ocul Pharmacol Ther; 2020 Sep; 36(7):497-511. PubMed ID: 32391735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.